MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
14.75
-1.62
-9.90%
After Hours: 14.75 0 0.00% 19:30 11/10 EST
OPEN
15.24
PREV CLOSE
16.37
HIGH
15.87
LOW
14.09
VOLUME
47.20K
TURNOVER
--
52 WEEK HIGH
72.60
52 WEEK LOW
9.45
MARKET CAP
16.36M
P/E (TTM)
-9.3372
1D
5D
1M
3M
1Y
5Y
1D
Jasper Therapeutics Consensus Price Target Increased by 2,900% to $267.75
NASDAQ · 1d ago
Jasper Therapeutics, Inc. Announces Results of Warrant Purchase Offer
NASDAQ · 1d ago
Jasper Therapeutics Reports Majority Warrant Tender Offer Participation
TipRanks · 1d ago
Weekly Report: what happened at JSPR last week (1102-1106)?
Weekly Report · 1d ago
Jasper Therapeutics trading halted, news pending
TipRanks · 5d ago
Jasper Therapeutics To Implement 1-for-30 Reverse Stock Split
NASDAQ · 6d ago
Jasper Therapeutics shares tank after announcing 1-for-30 reverse stock split
Seeking Alpha · 6d ago
*Jasper Therapeutics Announces 1-For-30 Reverse Stk Split >JSPR
Dow Jones · 6d ago
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.